Basic Principles and Rationale for HIV PrEP

This is a PDF version of the following document:
Module 1: HIV PrEP Fundamentals
Lesson 1: Basic Principles and Rationale for HIV PrEP

You can always find the most up-to-date version of this document at https://www.hivprep.uw.edu/go/hiv-prep-fundamentals/basic-principles-rationale-hiv-prep/core-concept/all.

Background

What is HIV Preexposure Prophylaxis (PrEP)?

HIV preexposure prophylaxis (PrEP) is the process when a person without HIV takes antiretroviral medications to prevent the acquisition of HIV. The goal of HIV PrEP is to prevent new HIV infections.

Need for HIV PrEP

In the United States, there is an immediate need to increase the availability, implementation, and use of HIV PrEP. The following summarizes the rationale for why a major scale-up in HIV PrEP is needed in the United States.

- **New HIV Infections Have Not Significantly Decreased**: The number of new HIV infections continues to occur at a substantial rate in the United States—estimated at about 32,000 new HIV infections per year.[1]
- **HIV PrEP is Effective**: When taken as prescribed, HIV PrEP is more than 90% effective for preventing sexual acquisition of HIV and approximately 70% effective in preventing HIV acquisition among people who inject drugs.[2,3,4]
- **HIV PrEP is Underutilized**: Overall, only about one in three persons who would benefit from HIV PrEP are receiving HIV PrEP.[5]
- **HIV PrEP is Usually Covered**: Most insurance plans and state Medicaid programs cover HIV PrEP, including laboratory and medication costs. In addition, some options may exist for persons who do not have medical insurance and are not receiving Medicaid.[6]

HIV PrEP Fundamentals Training Module

This *HIV National PrEP Curriculum HIV PrEP Fundamentals* training module is designed for health care professionals who are interested in any aspect of providing HIV PrEP. In the United States, a larger number of trained clinicians are needed to meet the growing demand for HIV PrEP. Multiple studies have shown that increasing medical provider awareness and knowledge about HIV PrEP is associated with an increased likelihood of prescribing HIV PrEP. More clinicians are needed with an interest and skill to provide HIV PrEP. Health care professionals who complete the HIV PrEP Fundamentals module training and receive a passing score on the 20-question, open-book, open-website, final assessment will receive a *National HIV PrEP Curriculum: HIV PrEP Training Certificate*. The major goal of this *HIV PrEP Fundamentals* module is to provide health professionals with the basic knowledge, skills, and core competencies to achieve the following:

1. Identify persons who are candidates for and may benefit from HIV PrEP
2. Perform a baseline evaluation prior to starting HIV PrEP
3. Choose an appropriate HIV PrEP regimen for the HIV PrEP candidate
4. Effectively monitor someone who is receiving HIV PrEP

Coverage and Goals for HIV PrEP in the United States

In 2019, the United States Department of Health and Human Services (HHS) launched the Ending the HIV Epidemic (EHE) initiative with a stated goal to reduce new HIV infections in the United States by 90% by the year 2030, with the achievement of this goal accomplished through the scale-up of HIV prevention and treatment strategies.[7] The use of HIV PrEP is a key component of the Ending the HIV Epidemic initiative, which has a year 2025 goal to increase HIV PrEP coverage to 50% in the United States—meaning that 50% of people with an indication for HIV PrEP will have HIV PrEP prescribed for them.[7] In recent years, the Centers for Disease Control and Prevention (CDC) has regularly published data on HIV PrEP coverage in the United States, which is defined as the number of persons 16 years of age and older having been prescribed HIV PrEP during the specified year divided by the estimated number of persons 16 years of age and older who had one or more indications for HIV PrEP during the specified year.[5] Data from 2022 indicate HIV PrEP coverage of 36% in the United States, which has increased significantly since 2017.[5] (Figure 1)[Q] HIV PrEP Prescribing in United States

Data to Support HIV PrEP

HIV PrEP Efficacy

Based on multiple HIV PrEP studies, available data suggest that oral and injectable HIV PrEP has an efficacy of at least 90% for preventing new sexual acquisition of HIV when taken as prescribed.[6] Three medications have been approved by the U.S. Food and Drug Administration (FDA) as HIV PrEP for the prevention of sexual acquisition of HIV: tenofovir DF-emtricitabine (TDF/FTC), tenofovir alafenamide-emtricitabine (TAF-FTC), and long-acting injectable cabotegravir (CAB-LA). The efficacy of HIV PrEP for people who inject drugs has not been as thoroughly studied, but available data suggest oral HIV PrEP with TDF-FTC has an efficacy of at least 70% in preventing the acquisition of HIV in people who inject drugs.[6] Multiple studies have shown that HIV PrEP medication adherence is a critical factor in the efficacy of this approach to prevent HIV acquisition.[6]

Major HIV PrEP Studies

The following summaries provide an overview of key studies that have evaluated the efficacy of HIV PrEP with the three medications that are approved for HIV PrEP. These studies are presented in alphabetical order based on the name that is most often used when the study is discussed. Note that each study has a brief name (shown in blue), followed by the medication that was studied, the patient population in the trial, and the formal name of the trial. In addition, click on the blue study name to see PowerPoint slides (with PDF and PPT download options) that summarize each trial.

- ATN 110 **[Tenofovir DF-emtricitabine / Adolescents]: In 2013, the Adolescent Trials Network 110 (ATN 110) study enrolled 200 adolescent males (aged 18 to 22 years) who have sex with other males to receive open-label TDF-emtricitabine (TDF-FTC) for HIV PrEP.[8] Using tenofovir diphosphate levels in dried blood spots as a marker for HIV PrEP medication adherence, the investigators concluded there was a major decline in adherence at week 24.[8] The rates of sexually transmitted infections were high at baseline (22% of participants) and remained high throughout the study.[8]**
- ATN 113 **[Tenofovir DF-emtricitabine / Adolescents]: The Adolescent Trials Network 113 (ATN 113) study was conducted in multiple cities in the United States, and it enrolled 78 adolescent males (15 to 17 years of age) who have sex with other males.[9] All participants received open-label daily oral tenofovir DF-emtricitabine (TDF-FTC) for HIV PrEP.[9] The TDF-FTC for HIV PrEP was found to be safe and well tolerated, but medication adherence, based on tenofovir diphosphate levels in dried blood spots, decreased markedly over time during the study.[9] The HIV seroconversion rate was 6.4 per 100 person-years, and the incidence of sexually transmitted infections was 18 per 100 person-years.[9]**
- Bangkok Tenofovir **[Tenofovir DF / PWID]: The Bangkok Tenofovir Study (BTS) was a phase 2/3, CDC-sponsored, double-blind, placebo-controlled trial that randomized 2,413 HIV-seronegative persons who inject drugs (PWID) to receive either daily oral tenofovir DF (TDF) or placebo.[2] All participants also received access to addiction support services, methadone programs, bleach for cleaning needles, condoms, and primary care medical services.[2] After a median follow-up time of 4.6 years, the relative risk reduction in HIV was 49% among study participants in the TDF arm; the relative risk reduction was 70% in a subgroup analysis of individuals with detectable plasma tenofovir levels.[2]**
- DISCOVER **[Tenofovir alafenamide-emtricitabine versus Tenofovir DF-emtricitabine / MSM and TGW]: This phase 3, randomized, double-blind trial compared the safety and efficacy of daily oral tenofovir alafenamide-emtricitabine (TAF-FTC) with daily oral tenofovir DF-emtricitabine (TDF-FTC) for HIV PrEP in adult men who have sex with men (MSM) and adult transgender women who have sex with men.[10] Investigators enrolled a total of 5,387 persons in the United States and Canada, of whom 1% were transgender women.[10] Primary efficacy analysis at week 48 (for all participants) and week 96 (for half the**

participants) indicated the incidence of documented new HIV infections in the daily TAF-FTC arm (0.16 per 100 person-years) was similar to the daily TDF-FTC arm (0.34 per 100 person-years).[10] Participants receiving TAF-FTC, when compared with those receiving TDF-FTC, had favorable bone mineral density measurements and biomarkers of renal safety but experienced more weight gain (about 1.2 kg difference).[10]

- **HPTN 083 [Cabotegravir versus Tenofovir DF-emtricitabine / MSM and TGW]: The HIV Prevention Trials Network (HPTN) 083 study was a randomized, double-blind, double-dummy, noninferiority trial comparing long-acting, injectable cabotegravir (CAB-LA) with daily oral tenofovir DF–emtricitabine (TDF-FTC) for the prevention of HIV infection in cisgender MSM and transgender women who have sex with men.[11] The cabotegravir regimen consisted of a 5-week lead-in phase with oral cabotegravir (30 mg daily), followed by 2 doses of CAB-LA (600 mg) 4 weeks apart, followed by CAB-LA every 8 weeks.[11] In total, 4,566 participants were randomized. There were 39 new HIV infections (incidence 1.22 per 100 person-years) in the TDF-FTC group and 13 infections (incidence 0.41 per 100 person-years) in the CAB-LA arm.[11] CAB-LA was superior to TDF-FTC for the prevention of HIV in MSM and transgender women; the superior efficacy of CAB-LA was driven largely by imperfect adherence to the oral TDF-FTC.[11]**
- **HPTN 084 (LIFE Study) [Cabotegravir versus tenofovir DF-emtricitabine / Cisgender Women]: The HIV Prevention Trials Network (HPTN) 084 study was a phase IIb/3, randomized, double-blind trial comparing long-acting, injectable cabotegravir (CAB-LA) versus daily oral tenofovir DF-emtricitabine (TDF-FTC) for the prevention of HIV infection in cisgender women at risk for acquiring HIV.[12] A total of 3,224 participants enrolled and were randomized.[12] The cabotegravir regimen consisted of a 5-week lead-in phase with oral cabotegravir (30 mg daily), followed by 2 doses of CAB-LA (600 mg) 4 weeks apart, followed by CAB-LA every 8 weeks.[12] There were 34 new HIV infections (incidence 1.79 per 100 person-years) in the TDF-FTC group versus 4 infections (incidence 0.21 per 100 person-years) in the CAB-LA arm. The CAB-LA arm was superior to the TDF-FTC arm for the prevention of HIV acquisition in cisgender women.[12]**
- **IPERGAY [On-demand tenofovir DF-emtricitabine / MSM]: The ANRS Intervention Préventive de l'Exposition aux Risques avec et pour les Gays (IPERGAY) study was a phase 3, randomized, double-blind, placebo-controlled trial in France and Canada evaluating the efficacy of on-demand oral tenofovir DF-emtricitabine (TDF-FTC), taken before and after sexual activity for the prevention of HIV among 400 sexually active MSM and transgender women who have sex with men.[13] Participants were evaluated at weeks 4 and 8, and then every 8 weeks thereafter.[13] In addition, at each visit, all participants received a comprehensive package of risk reduction interventions. Adherence was measured by pill count, structured interviews, and, in some participants, by plasma emtricitabine levels.[13] After a median follow-up of 9.3 months, the relative risk reduction in HIV infection was 86% in the on-demand TDF-FTC arm compared to the placebo arm.[13]**
- **IPrEx [Tenofovir DF-emtricitabine / MSM and TGW]: The Preexposure Initiative (iPrEx) study was a phase 3, randomized, double-blind, placebo-controlled trial conducted in Peru, Ecuador, Brazil, Thailand, South Africa, and the United States that enrolled 2,499 HIV-seronegative adults, including 2,470 MSM and 29 transgender women who have sex with men.[14] Participants were randomly assigned to receive a daily oral dose of tenofovir DF-emtricitabine (TDF-FTC) or placebo. Investigators evaluated study participants every 4 weeks with an interview, HIV testing, counseling about risk reduction and adherence to HIV PrEP medication doses, pill count, and dispensing of pills and condoms. This study documented 44% fewer new HIV infections among those prescribed daily TDF-FTC for HIV PrEP when compared to those who received placebo.[14]**
- **Partners PrEP [Tenofovir DF-emtricitabine or tenofovir DF / Heterosexual Couples]: The Partners PrEP trial was a phase 3, randomized, double-blind, placebo-controlled study that enrolled 4,758 HIV-serodifferent heterosexual couples in Uganda and Kenya. The investigators randomized the HIV-seronegative partners to receive either daily oral tenofovir DF (TDF), tenofovir DF-emtricitabine (TDF-FTC), or placebo for the prevention of**

HIV acquisition.[15] The HIV-seropositive partners had a median CD4 count of 495 cells/mm^3 and were not receiving antiretroviral therapy (because they were not eligible per local treatment guidelines that existed at the time the study was conducted).[15] The trial was stopped after an interim analysis showed statistically significant lower HIV transmission rates in both the TDF and TDF-FTC groups compared with the placebo group; investigators reported a 75% reduction in HIV acquisition among the partners who were HIV-seronegative and taking daily oral TDF-FTC, and a 67% reduction among those taking only daily oral TDF.[15] Adherence was high, as measured by pills dispensed, pill count, and random plasma drug level testing.

- PROUD **[Tenofovir DF-emtricitabine / MSM]: The Preexposure Option for Reducing HIV in the UK (PROUD) study was a phase 4, randomized, open-label study at 13 clinics in England that evaluated the efficacy of daily oral tenofovir DF-emtricitabine (TDF-FTC) for the prevention of HIV among sexually active men without HIV who reported condomless anal sex with men in the previous 90 days.[16] The 544 study participants were randomized to receive daily TDF-FTC either immediately upon enrollment or after a deferral period of 1 year. The investigators assessed sexual risk behaviors and adherence via daily diaries and monthly questionnaires; plasma tenofovir samples were collected from some participants as an objective measure of adherence. The relative risk reduction in HIV infection in the immediate arm (participants who took TDF-FTC daily) was 86%.[16]**
- TDF2 **[Tenofovir DF-emtricitabine / Heterosexual Men and Heterosexual Women]: The Botswana TDF/FTC Oral HIV Prophylaxis Trial (TDF2), a phase 3, randomized, double-blind, placebo-controlled study of the safety and efficacy of daily oral tenofovir DF-emtricitabine (TDF-FTC), enrolled 1,219 heterosexual men and women in Botswana who had tested negative for HIV.[17] In this study, daily oral use of TDF-FTC resulted in a 62% reduction in HIV acquisition when compared with placebo.[17] Adherence by pill count was 84% in both medication groups.**

Visual Abstracts of Major HIV PrEP Studies

The HIV PrEP visual abstracts shown below provide brief visual summaries (Figure 2) for each of the major HIV PrEP studies listed above. Note this visual abstract series can be downloaded as a PDF document.

Addressing Stigma and Barriers Related to HIV PrEP Use

Disparities in HIV PrEP Access and Use

Despite the well-established efficacy of HIV PrEP, it is underutilized and under-prescribed in the United States. The low rate of uptake of HIV PrEP is the result of a complex interplay of social, economic, environmental, behavioral, and educational factors related to social determinants of health—nonmedical factors that influence health outcomes. Further, there are major systemic and structural barriers that lead to disparities in HIV PrEP access and usage. For example, in recent years, Black Americans represented about 40% of new HIV infections in the United States but accounted for only 14% of persons taking HIV PrEP.[5] Disparities exist when examining HIV PrEP usage by race/ethnicity, geographic location, income, insurance status, education level, substance use, and other factors.[18,19,20,21,22] A 2020 systematic review and meta-analysis highlighted disproportionately low rates of HIV PrEP prescriptions in the South and in youth.[23] There are differences in HIV PrEP insurance qualifications by region and discrepancies in access by state and whether the state has expanded Medicaid coverage.[24,25,26] Availability of HIV PrEP clinics is uneven and was found to be disproportionately lacking in counties with more residents living in poverty, lacking health insurance, and in persons identifying as African American or Latino/Hispanic.[27] In the United States, cisgender women and transgender women have relatively lower rates of HIV PrEP use when compared with HIV PrEP use among cisgender men who have sex with men (MSM).[28,29,30,31,32] The CDC HIV PrEP usage data show major differences in HIV PrEP usage in the United States based on sex (assigned at birth), age, race/ethnicity (Figure 3).[5]

[Q] HIV PrEP Prescribing in Different Populations

Barriers to Receiving HIV PrEP

A recent literature review identified multiple complex hurdles to HIV PrEP coverage in the United States, including structural, social, and behavioral barriers.[33] Obstacles can exist at each step of the HIV PrEP care continuum, such as individual perception of HIV risk and awareness of HIV PrEP, access to a knowledgeable HIV PrEP provider, comfort discussing HIV PrEP with a health care professional, willingness to take HIV PrEP, concerns about medication side effects, and costs of HIV PrEP.[34] The HIV PrEP-related financial concerns include costs for medications, clinic visits, and the cost of laboratory monitoring.[35] Patient mistrust of the health care system and past traumatic experiences in health care may also contribute to the non-use of HIV PrEP.[36,37] Qualitative studies that engaged cisgender women found low perceived HIV risk, fear of partner reactions, and worry of stigmatization to be significant barriers.[38] Medical provider factors that may contribute to HIV PrEP barriers include lack of medical awareness, skills, knowledge, training, and willingness to prescribe HIV PrEP.[39,40,41] A survey of sexual minority male couples in New York found that access to a health care provider who was knowledgeable about HIV PrEP was a critical factor associated with their interest in taking HIV PrEP.[42]

Impact of Stigma on HIV PrEP Usage

Stigma is a major impediment to seeking and taking HIV PrEP, including stigma from health care professionals and fear of discrimination or discomfort raising the issue of HIV risk, whether secondary to sexual risk or injecting drugs.[33] The source of bias, whether implicit or explicit, may be related to a person's sexual orientation, gender expression, race/ethnicity, use of illicit drugs, and other overlapping and intersectional factors. Individuals seeking or taking HIV PrEP may be stereotyped in a number of ways.[43] A study in San Francisco identified an association between experiencing HIV PrEP-related stigma and being transgender or gender non-conforming, having a history of injecting drugs, being in an unstable housing situation, and having mental health issues.[44] A focus group study with African American young adults identified multiple stigma-related factors that reduced HIV PrEP uptake.[45] A systematic review that examined perceptions and beliefs about HIV PrEP among MSM and transgender women found that stigma and the quality of relationships with health care providers impacted the likelihood of pursuing HIV PrEP.[46] In addition to stigmatization at an

individual level, HIV PrEP stigma may occur at a community level and may be exacerbated by language and policy as part of public health campaigns, research, or state or federal laws.[47,48]

Addressing Stigma and Other Barriers to HIV PrEP Access

Overall, the barriers to HIV PrEP, including stigma, must be acknowledged, better understood, and addressed through interventions at the clinic, community, and systems level. User-centered approaches to promote improved access and reduce disparities in usage will contribute to disseminating HIV PrEP to those in need and to reducing the number of new infections in the country. The interventions needed to address the multiple structural and systemic barriers to HIV PrEP access are complicated, but the following measures can help in efforts to address and overcome these barriers.

- Take a stigma-informed and trauma-informed approach to HIV preventive care.[49] All health care professionals should use inclusive, non-stigmatizing messaging, since this is crucial for engaging individuals at risk for HIV acquisition and promoting HIV PrEP access, whether in a clinic setting or in larger public health campaigns.[43]
- Normalize HIV screening and conversations about HIV PrEP to help reduce stigmatization.
- Integrate HIV PrEP into routine primary care services, including at clinics that provide sexual health care, gender-affirming care, addiction treatment, and family planning services.[50,51,52] Ideally, such integrated services are combined with peer navigation and collaboration with community-based organizations.[53]
- Incorporate expansion of HIV PrEP delivery models, such as HIV PrEP via telemedicine, pharmacist-prescribed HIV PrEP, or home delivery; these expanded HIV PrEP delivery options can ease the burden of seeking a clinic and finding a knowledgeable provider and thus facilitate HIV PrEP.[54]
- Address medical provider education and financial support for HIV PrEP, as well as any technology-mediated models that facilitate HIV PrEP access, reduce barriers, and enhance medication adherence.[33]
- Utilize a community-informed approach to HIV PrEP messaging—meaning gathering community input on research, quality improvement interventions, and policy—to help optimize protocols and messaging and reduce the potential for stigmatization at a community level.[45]
- Create community partnerships to help connect individuals who may benefit from HIV PrEP with leaders from the community who can help with HIV PrEP education and support. Similarly, engage HIV PrEP navigators and other community advocates to help build relationships and overcome medical mistrust. Social support is another key facilitator of HIV PrEP acceptance and usage.[49]

Suggested viewing: For a more in depth discussion of this topic, see the lecture on this website by Dr. Latesha Elopre from the University of Alabama at Birmingham on PrEP—Stigma and Barriers (*22 minutes*).

Status Neutral Approach to HIV Prevention and Care

In 2022, in an effort to address stigma and health disparities related to HIV prevention and treatment, the CDC issued a brief on Status Neutral HIV Care and Service Delivery Eliminating Stigma and Reducing Health Disparities.[55] The status neutral approach incorporates HIV prevention and care into routine health care with the goal of delivering high quality, culturally-affirming health care and services to people with and without HIV, thereby advancing health equity and reducing disparities.[55] The rationale for this approach is that many of the clinical and social services needed for HIV treatment and HIV prevention are the same, and there are advantages of combining these services in a single location for people with and without HIV. When using this approach with HIV testing, persons who test negative should receive prevention services, including HIV PrEP, if indicated, and persons who test positive should promptly receive HIV treatment (Figure 4).[55]

Watch the Video below on **The Status Neutral Approach: A Whole Person Approach** by Demtre C. Daskalakis, MD, MPH, CDC Director of the Division of HIV Prevention (*12 minutes*).

Summary Points

- New HIV infections continue to occur at a substantial rate in the United States, estimated at 32,000 new infections per year.
- HIV PrEP is the use of medications to prevent HIV acquisition and reduce HIV infection rates, and multiple HIV PrEP studies in the United States and globally have demonstrated the efficacy and safety of HIV PrEP for preventing HIV acquisition.
- Among people who take HIV PrEP medications as prescribed, the medications are more than 90% effective for preventing sexual acquisition of HIV and approximately 70% effective in preventing HIV acquisition among people who inject drugs.
- In 2019, the U.S. Department of Health and Human Services (HHS) launched the Ending the HIV Epidemic (EHE) initiative with a goal to increase HIV PrEP coverage to 50% by 2025 and reduce new HIV infections by 90% (from baseline) by 2030.
- Multiple, complex, intersectional, structural, social, and behavioral barriers at patient and provider levels contribute to the non-use of HIV PrEP in the United States.
- Patient barriers include individual perception of HIV risk and awareness of HIV PrEP, access to and comfort discussing HIV PrEP with a knowledgeable health care provider, willingness to take HIV PrEP, and costs related to HIV PrEP.
- There exist significant disparities in HIV PrEP uptake by age, race/ethnicity, sex at birth, and geographic location.
- Medical provider factors that may contribute to HIV PrEP barriers include lack of medical awareness, skills, knowledge, training, and willingness to prescribe HIV PrEP.
- Stigma is a major impediment to seeking and taking HIV PrEP, including stigma from health care professionals and fear of discrimination or discomfort raising the issue of HIV risk, whether secondary to sexual risk or injecting drugs.
- Strategies to address HIV PrEP stigma and barriers include stigma- and trauma-informed care; normalization and integration of HIV screening and HIV PrEP in primary care services; expansion of HIV PrEP delivery models and provider education; community involvement in HIV PrEP messaging; and addressing the financial support needs of medical providers and social needs of HIV PrEP users.

Citations

1. Centers for Disease Control and Prevention. Estimated HIV Incidence and Prevalence in the United States, 2017–2021. HIV Surveillance Supplemental Report. 2023;28(3). Published May 2023.
[CDC] -

2. Choopanya K, Martin M, Suntharasamai P, et al. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2013;381:2083-90.
[PubMed Abstract] -

3. Castillo-Mancilla JR, Zheng JH, Rower JE, et al. Tenofovir, emtricitabine, and tenofovir diphosphate in dried blood spots for determining recent and cumulative drug exposure. AIDS Res Hum Retroviruses. 2013;29:384-90.
[PubMed Abstract] -

4. Grant RM, Anderson PL, McMahan V, et al. Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study. Lancet Infect Dis. 2014;14:820-9.
[PubMed Abstract] -

5. Centers for Disease Control and Prevention. Core indicators for monitoring the Ending the HIV Epidemic initiative (preliminary data): National HIV Surveillance System data reported through September 2022; and preexposure prophylaxis (PrEP) data reported through June 2023. HIV Surveillance Data Tables 2023;4(No. 4). Published December 2023.
[CDC] -

6. Centers for Disease Control and Prevention: US Public Health Service: Preexposure prophylaxis for the prevention of HIV infection in the United States—2021 Update: a clinical practice guideline. December 2021:1-108.
[CDC] -

7. Fauci AS, Redfield RR, Sigounas G, Weahkee MD, Giroir BP. Ending the HIV Epidemic: A Plan for the United States. JAMA. 2019;321:844-845.
[PubMed Abstract] -

8. Hosek SG, Rudy B, Landovitz R, et al. An HIV Preexposure Prophylaxis Demonstration Project and Safety Study for Young MSM. J Acquir Immune Defic Syndr. 2017;74:21-9.
[PubMed Abstract] -

9. Hosek SG, Landovitz RJ, Kapogiannis B, et al. Safety and Feasibility of Antiretroviral Preexposure Prophylaxis for Adolescent Men Who Have Sex With Men Aged 15 to 17 Years in the United States. JAMA Pediatr. 2017;171:1063-71.
[PubMed Abstract] -

10. Mayer KH, Molina JM, Thompson MA, et al. Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial. Lancet. 2020;396:239-54.
[PubMed Abstract] -

11. Landovitz RJ, Donnell D, Clement ME, et al. Cabotegravir for HIV prevention in cisgender men and transgender women. N Engl J Med. 2021;385:595-608.

[PubMed Abstract] -

12. Delany-Moretlwe S, Hughes JP, Bock P, et al. Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial. Lancet. 2022;399:1779–89.
[PubMed Abstract] -

13. Molina JM, Capitant C, Spire B, et al. On-demand preexposure prophylaxis in men at high risk for HIV-1 infection. N Engl J Med. 2015;373:2237-46.
[PubMed Abstract] -

14. Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363:2587-99.
[PubMed Abstract] -

15. Baeten JM, Donnell D, Ndase P, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012;367:399-410.
[PubMed Abstract] -

16. McCormack S, Dunn DT, Desai M, et al. Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial. Lancet. 2016;387:53-60.
[PubMed Abstract] -

17. Thigpen MC, Kebaabetswe PM, Paxton LA, et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med. 2012;367:423-34.
[PubMed Abstract] -

18. Shover CL, Javanbakht M, Shoptaw S, et al. HIV Preexposure Prophylaxis Initiation at a Large Community Clinic: Differences Between Eligibility, Awareness, and Uptake. Am J Public Health. 2018;108:1408-17.
[PubMed Abstract] -

19. Kanny D, Jeffries WL 4th, Chapin-Bardales J, et al. Racial/Ethnic Disparities in HIV Preexposure Prophylaxis Among Men Who Have Sex with Men - 23 Urban Areas, 2017. MMWR Morb Mortal Wkly Rep. 2019;68:801-6.
[PubMed Abstract] -

20. Allen DC, Rabionet SE, Popovici I, Zorrilla CD. Acknowledging and addressing the gender disparity in pre-exposure prophylaxis use for HIV prevention. J Pharm Health Serv Res. 2022;13:168-71.
[PubMed Abstract] -

21. Doherty R, Walsh JL, Quinn KG, John SA. Association of Race and Other Social Determinants of Health With HIV Pre-Exposure Prophylaxis Use: A County-Level Analysis Using the PrEP-to-Need Ratio. AIDS Educ Prev. 2022;34:183-194.
[PubMed Abstract] -

22. Hojilla JC, Hurley LB, Marcus JL, et al. Characterization of HIV preexposure prophylaxis use behaviors and HIV incidence among US adults in an integrated health care system. JAMA Netw Open. 2021;4:e2122692.
[PubMed Abstract] -

23. Kamitani E, Johnson WD, Wichser ME, Adegbite AH, Mullins MM, Sipe TA. Growth in Proportion and Disparities of HIV PrEP Use Among Key Populations Identified in the United States National Goals: Systematic Review and Meta-analysis of Published Surveys. J Acquir Immune Defic Syndr.

2020;84:379-86.
[PubMed Abstract] -

24. McManus KA, Powers S, Killelea A, Tello-Trillo S, Rogawski McQuade E. Regional Disparities in Qualified Health Plans' Prior Authorization Requirements for HIV Pre-exposure Prophylaxis in the United States. JAMA Netw Open. 2020;3:e207445.
[PubMed Abstract] -

25. Patel RR, Mena L, Nunn A, et al. Impact of insurance coverage on utilization of pre-exposure prophylaxis for HIV prevention. PLoS One. 2017;12:e0178737.
[PubMed Abstract] -

26. Powers SD, Rogawski McQuade ET, Killelea A, Horn T, McManus KA. Worsening Disparities in State-Level Uptake of Human Immunodeficiency Virus Preexposure Prophylaxis, 2014-2018. Open Forum Infect Dis. 2021;8:ofab293.
[PubMed Abstract] -

27. Siegler AJ, Bratcher A, Weiss KM, Mouhanna F, Ahlschlager L, Sullivan PS. Location location location: an exploration of disparities in access to publicly listed pre-exposure prophylaxis clinics in the United States. Ann Epidemiol. 2018;28:858-64.
[PubMed Abstract] -

28. Aaron E, Blum C, Seidman D, et al. Optimizing Delivery of HIV Preexposure Prophylaxis for Women in the United States. AIDS Patient Care STDS. 2018;32:16-23.
[PubMed Abstract] -

29. Reisner SL, Jadwin-Cakmak L, White Hughto JM, Martinez M, Salomon L, Harper GW. Characterizing the HIV Prevention and Care Continua in a Sample of Transgender Youth in the U.S. AIDS Behav. 2017;21:3312-27.
[PubMed Abstract] -

30. Sevelius JM, Keatley J, Calma N, Arnold E. 'I am not a man': Trans-specific barriers and facilitators to PrEP acceptability among transgender women. Glob Public Health. 2016;11:1060-75.
[PubMed Abstract] -

31. Watson CW, Pasipanodya E, Savin MJ, et al. Barriers and Facilitators to PrEP Initiation and Adherence Among Transgender and Gender Non-Binary Individuals in Southern California. AIDS Educ Prev. 2020;32:472-85.
[PubMed Abstract] -

32. Wilson EC, Turner CM, Arayasirikul S, et al. Disparities in the PrEP continuum for trans women compared to MSM in San Francisco, California: results from population-based cross-sectional behavioural surveillance studies. J Int AIDS Soc. 2020;23 Suppl 3:e25539.
[PubMed Abstract] -

33. Mayer KH, Agwu A, Malebranche D. Barriers to the Wider Use of Pre-exposure Prophylaxis in the United States: A Narrative Review. Adv Ther. 2020;37:1778-1811.
[PubMed Abstract] -

34. Kelley CF, Kahle E, Siegler A, et al. Applying a PrEP Continuum of Care for Men Who Have Sex With Men in Atlanta, Georgia. Clin Infect Dis. 2015;61:1590-7.
[PubMed Abstract] -

35. Srikanth K, Killelea A, Strumpf A, Corbin-Gutierrez E, Horn T, McManus KA. Associated Costs Are a

Barrier to HIV Preexposure Prophylaxis Access in the United States. Am J Public Health. 2022;112:834-8.
[PubMed Abstract] -

36. Jaiswal J, Halkitis PN. Towards a More Inclusive and Dynamic Understanding of Medical Mistrust Informed by Science. Behav Med. 2019;45:79-85.
[PubMed Abstract] -

37. Kimball D, Rivera D, Gonzales M 4th, Blashill AJ. Medical Mistrust and the PrEP Cascade Among Latino Sexual Minority Men. AIDS Behav. 2020;24:3456-61.
[PubMed Abstract] -

38. O'Malley TL, Krier SE, Bainbridge M, Hawk ME, Egan JE, Burke JG. Women's perspectives on barriers to potential PrEP uptake for HIV prevention: HIV risk assessment, relationship dynamics and stigma. Cult Health Sex. 2022:1-15.
[PubMed Abstract] -

39. Smith DK, Mendoza MC, Stryker JE, Rose CE. PrEP Awareness and Attitudes in a National Survey of Primary Care Clinicians in the United States, 2009-2015. PLoS One. 2016;11:e0156592.
[PubMed Abstract] -

40. Blackstock OJ, Moore BA, Berkenblit GV, et al. A Cross-Sectional Online Survey of HIV Pre-Exposure Prophylaxis Adoption Among Primary Care Physicians. J Gen Intern Med. 2017;32:62-70.
[PubMed Abstract] -

41. Zhang C, McMahon J, Fiscella K, et al. HIV Pre-Exposure Prophylaxis Implementation Cascade Among Health Care Professionals in the United States: Implications from a Systematic Review and Meta-Analysis. AIDS Patient Care STDS. 2019;33:507-27.
[PubMed Abstract] -

42. Bosco SC, Pawson M, Parsons JT, Starks TJ. Biomedical HIV Prevention among Gay Male Couples: A Qualitative Study of Motivations and Concerns. J Homosex. 2021;68:1353-70.
[PubMed Abstract] -

43. Calabrese SK. Understanding, Contextualizing, and Addressing PrEP Stigma to Enhance PrEP Implementation. Curr HIV/AIDS Rep. 2020;17:579-88.
[PubMed Abstract] -

44. Bhatta DN, Hecht J, Facente SN. Factors associated with stigma related to HIV pre-exposure prophylaxis (PrEP) use among men who have sex with men (MSM). Sex Transm Infect. 2022;98:592-4.
[PubMed Abstract] -

45. Kerr J, Ayangeakaa S, Bullock NAA, et al. A Qualitative Exploration of Various Stigmas Impacting HIV Pre-Exposure Prophylaxis (PrEP) Uptake Among African American Young Adults. Fam Community Health. 2022;45:218-27.
[PubMed Abstract] -

46. Matacotta JJ, Rosales-Perez FJ, Carrillo CM. HIV Preexposure Prophylaxis and Treatment as Prevention - Beliefs and Access Barriers in Men Who Have Sex With Men (MSM) and Transgender Women: A Systematic Review. J Patient Cent Res Rev. 2020;7:265-74.
[PubMed Abstract] -

47. Bonett S, Meanley S, Elsesser S, Bauermeister J. State-Level Discrimination Policies And HIV Pre-Exposure Prophylaxis Adoption Efforts In The US. Health Aff (Millwood). 2020;39:1575-82.

[PubMed Abstract] -

48. Golub SA. PrEP Stigma: Implicit and Explicit Drivers of Disparity. Curr HIV/AIDS Rep. 2018;15:190-7.
[PubMed Abstract] -

49. Stephenson R, Chavanduka TMD, Sullivan SP, Mitchell JW. Pre-Exposure Prophylaxis Stigma and Beliefs in the Efficacy of Pre-Exposure Prophylaxis: An Analysis of a Cross-Sectional Survey of Male Couples in the United States. J Assoc Nurses AIDS Care. 2022;33:406-20.
[PubMed Abstract] -

50. Calabrese SK, Krakower DS, Mayer KH. Integrating HIV Preexposure Prophylaxis (PrEP) Into Routine Preventive Health Care to Avoid Exacerbating Disparities. Am J Public Health. 2017;107:1883-9.
[PubMed Abstract] -

51. Lama JR, Mayer KH, Perez-Brumer AG, et al. Integration of Gender-Affirming Primary Care and Peer Navigation With HIV Prevention and Treatment Services to Improve the Health of Transgender Women: Protocol for a Prospective Longitudinal Cohort Study. JMIR Res Protoc. 2019;8:e14091.
[PubMed Abstract] -

52. Rich KM, Bia J, Altice FL, Feinberg J. Integrated Models of Care for Individuals with Opioid Use Disorder: How Do We Prevent HIV and HCV? Curr HIV/AIDS Rep. 2018;15:266-75.
[PubMed Abstract] -

53. Mayer KH, Chan PA, R Patel R, Flash CA, Krakower DS. Evolving Models and Ongoing Challenges for HIV Preexposure Prophylaxis Implementation in the United States. J Acquir Immune Defic Syndr. 2018;77:119-27.
[PubMed Abstract] -

54. Garrison LE, Haberer JE. Pre-exposure Prophylaxis Uptake, Adherence, and Persistence: A Narrative Review of Interventions in the U.S. Am J Prev Med. 2021;61:S73-S86.
[PubMed Abstract] -

55. Centers for Disease Control and Prevention. Issue Brief: Status Neutral HIV Care and Service Delivery Eliminating Stigma and Reducing Health Disparities.
[CDC] -

References

- Deutsch MB, Glidden DV, Sevelius J, et al. HIV pre-exposure prophylaxis in transgender women: a subgroup analysis of the iPrEx trial. Lancet HIV. 2015;2:e512-9.
[PubMed Abstract] -

- Evans KN, Hassan R, Townes A, Buchacz K, Smith DK. The Potential of Telecommunication Technology to Address Racial/Ethnic Disparities in HIV PrEP Awareness, Uptake, Adherence, and Persistence in Care: A Review. AIDS Behav. 2022;26:3878-88.
[PubMed Abstract] -

- Herron PD. Current Perspectives on the Impact of Pre-Exposure Prophylaxis Stigma Regarding Men Who Have Sex with Men in the United States. HIV AIDS (Auckl). 2020;12:187-92.
[PubMed Abstract] -

- Kerr J, Ayangeakaa S, Combs R, et al. Community-Informed Development of a Campaign to Increase HIV Pre-exposure Prophylaxis (PrEP) Awareness Among African-American Young Adults. J Racial Ethn

Health Disparities. 2021;8:901-11.
[PubMed Abstract] -

- Mann-Jackson L, Alonzo J, Garcia M, et al. Using community-based participatory research to address STI/HIV disparities and social determinants of health among young GBMSM and transgender women of colour in North Carolina, USA. Health Soc Care Community. 2021;29:e192-e203.
[PubMed Abstract] -

- Price DM, Unger Z, Wu Y, Meyers K, Golub SA. Clinic-Level Strategies for Mitigating Structural and Interpersonal HIV Pre-Exposure Prophylaxis Stigma. AIDS Patient Care STDS. 2022;36:115-22.
[PubMed Abstract] -

- US Preventive Services Task Force; Barry MJ, Nicholson WK, et al. Preexposure Prophylaxis to Prevent Acquisition of HIV: US Preventive Services Task Force Recommendation Statement. JAMA. 2023;330:736-45.
[PubMed Abstract] -

Figures

Figure 1 HIV PrEP Coverage in the United States

Source: Centers for Disease Control and Prevention. Core indicators for monitoring the Ending the HIV Epidemic initiative (preliminary data): National HIV Surveillance System data reported through September 2022; and preexposure prophylaxis (PrEP) data reported through June 2023. HIV Surveillance Data Tables 2023;4(No. 4). Published December 2023.

This is a dynamic visualization. Please visit our website to experience this dynamic content.



Figure 2 HIV PrEP Studies: Visual Abstract Guide

National HIV PrEP Curriculum

For more information guides visit **hivprep.uw.edu**

VISUAL ABSTRACTS

HIV PrEP Studies

David H. Spach, MD[1] / Brian R. Wood, MD[1] / Kevin L. Ard, MD[2]

TABLE OF CONTENTS

ABOUT THIS INFORMATION GUIDE

This visual abstract study series is intended for health care professionals involved in care of persons who may benefit from receiving HIV preexposure prophylaxis (PrEP). These visual abstracts provide relevant information pertaining to major HIV PrEP studies. This guide has been created and produced by the University of Washington Infectious Diseases Education & Assessment Program (IDEA) as part of the federally-funded *National HIV PrEP Curriculum* project.

PERMISSION TO USE THIS GUIDE

LAST UPDATED

This educational guide was last updated February 5, *2024*.

AUTHOR AFFILIATIONS
[1] Division of Allergy and Infectious Diseases / University of Washington
[2] Division of Infectious Diseases / Massachusetts General Hospital

THIS PROJECT WAS FUNDED BY THE CENTERS FOR DISEASE CONTROL AND PREVENTION AND THE HEALTH RESOURCES AND SERVICES ADMINISTRATION.

Figure 3 Disparities in HIV PrEP Coverage in the United States

Source: Centers for Disease Control and Prevention. Core indicators for monitoring the Ending the HIV Epidemic initiative (preliminary data): National HIV Surveillance System data reported through September 2022; and preexposure prophylaxis (PrEP) data reported through June 2023. HIV Surveillance Data Tables 2023;4(No. 4). Published December 2023.

This is a dynamic visualization. Please visit our website to experience this dynamic content.



Figure 4 Status Neutral HIV Prevention and Care

Source: Centers for Disease Control and Prevention. Issue Brief: Status Neutral HIV Care and Service Delivery Eliminating Stigma and Reducing Health Disparities.



Follow CDC guidelines to test people for HIV. Regardless of HIV status, quality care is the foundation of HIV prevention and effective treatment. Both pathways provide people with the tools they need to stay healthy and stop HIV.